[go: up one dir, main page]

AR106301A1 - Composiciones de pirrolpirimidina como inhibidores de quinasas - Google Patents

Composiciones de pirrolpirimidina como inhibidores de quinasas

Info

Publication number
AR106301A1
AR106301A1 ARP160103082A ARP160103082A AR106301A1 AR 106301 A1 AR106301 A1 AR 106301A1 AR P160103082 A ARP160103082 A AR P160103082A AR P160103082 A ARP160103082 A AR P160103082A AR 106301 A1 AR106301 A1 AR 106301A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
substituted
halo
hydroxyl
Prior art date
Application number
ARP160103082A
Other languages
English (en)
Inventor
Wang Xiaobo
Xu Wanhong
Xu Xiao
Wu Jian
Mo Xiaopeng
Weng Bojie
Bao Yimei
Dai Kongen
Hua Yuning
Chen Yile
Liu Jia
Mao Long
Original Assignee
Acea Biosciences Inc
Acea Bio Hangzhou Co Ltd
Acea Pharmaceutical Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acea Biosciences Inc, Acea Bio Hangzhou Co Ltd, Acea Pharmaceutical Res Co Ltd filed Critical Acea Biosciences Inc
Publication of AR106301A1 publication Critical patent/AR106301A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica caracterizada porque comprende: (a) un compuesto de la fórmula (1), en donde X¹ es O, NH, o S; R¹ y R² son cada uno, independientemente, hidrógeno, halo, C₁₋₆ alquilo, o C₁₋₆ haloalquilo; R³ es halo, hidroxilo, C₁₋₆ alquilo, C₁₋₆ alcoxi, ciano, o nitro; n es 0, 1, 2, 3 ó 4; R⁴ es hidrógeno, C₁₋₆ alquilo, C₃₋₇ cicloalquilo, o -NR²²R²³; en donde el alquilo y el cicloalquilo no están sustituidos o están sustituidos con hidroxilo o amino; y R²² y R²³ son cada uno, independientemente, hidrógeno o C₁₋₆ alquilo; o R²² y R²³ tomados junto con el nitrógeno al que están unidos, forman un anillo heterocicloalquilo de entre 3 y 10 miembros; R⁵ es hidrógeno o C₁₋₄ alquilo; R⁶ y R⁷ son cada uno, independientemente, hidrógeno, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alcoxi, C₁₋₆ haloalcoxi, hidroxilo, ciano, o nitro; R⁸ es hidrógeno, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ alcoxi, C₁₋₆ haloalcoxi, hidroxilo, ciano, o nitro; R¹¹ y R¹² son cada uno, independientemente, hidrógeno o C₁₋₆ alquilo; Q es CR⁹ o N; donde R⁹ es hidrógeno, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ alcoxi, C₁₋₆ haloalcoxi, hidroxilo, ciano, o nitro; -NR¹⁸R¹⁹ es: (a) un compuesto de fórmula (2) ó (3); donde R¹⁰ se selecciona entre hidrógeno y C₁₋₆ alquilo; R¹⁵ es metilo no sustituido, o es C₂₋₄ alquilo no sustituido o sustituido con hidroxi, metoxi, o halo; y m es 1 ó 2; o (b) R¹⁹ y R⁹ se toman junto con los átomos a los que están unidos para formar un anillo heteroarilo de 5 ó 6 miembros, opcionalmente sustituido con C₁₋₆ alquilo, en donde el alquilo no está sustituido o está sustituido con amino, hidroxilo, halo, o un heterocicloalquilo conectado al N; y R¹⁸ es hidrógeno o C₁₋₆ alquilo, donde el alquilo no está sustituido o está sustituido con amino, o R¹⁸ está ausente para satisfacer la valencia del anillo heteroarilo; o Compuesto de fórmula (4), o una sal farmacéuticamente aceptable del compuesto de la fórmula (1) o Compuesto de fórmula (4); y (b) un agente de adsorción que reduce o suprime la formación de un dímero del compuesto, o una sal farmacéuticamente aceptable del mismo.
ARP160103082A 2015-10-09 2016-10-07 Composiciones de pirrolpirimidina como inhibidores de quinasas AR106301A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2015091536 2015-10-09

Publications (1)

Publication Number Publication Date
AR106301A1 true AR106301A1 (es) 2018-01-03

Family

ID=58487279

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103082A AR106301A1 (es) 2015-10-09 2016-10-07 Composiciones de pirrolpirimidina como inhibidores de quinasas

Country Status (13)

Country Link
US (1) US10533011B2 (es)
EP (1) EP3359159B1 (es)
JP (1) JP6889494B2 (es)
KR (1) KR20180067584A (es)
CN (1) CN107949388B (es)
AR (1) AR106301A1 (es)
AU (1) AU2016334141B2 (es)
BR (1) BR112018006939A2 (es)
CA (1) CA3001744C (es)
MX (1) MX2018004332A (es)
RU (1) RU2018115334A (es)
TW (1) TW201722431A (es)
WO (1) WO2017059702A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
WO2013106792A1 (en) * 2012-01-13 2013-07-18 Acea Biosciences Inc. Heterocyclic compounds and uses as anticancer agents.
CN112592334B (zh) 2013-07-11 2023-10-27 艾森医药公司 嘧啶衍生物作为激酶抑制剂
EP3359159B1 (en) 2015-10-09 2023-06-07 ACEA Therapeutics, Inc. Pharmaceutical compositions of a pyrrolopyrimidine kinase inhibitor, and methods of making same
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
EP3606925A1 (en) * 2017-04-07 2020-02-12 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
CN112424207B (zh) 2018-07-25 2024-03-19 诺华股份有限公司 Nlrp3炎性小体抑制剂
AU2018436086B2 (en) * 2018-08-09 2023-10-05 ACEA Therapeutics, Inc. Process for manufacture of (S)-N-(3-((2-((4-((1-acetylpyrrolidin-3-yl)(methyl)amino)phenyl)amino)-5-methoxypyrimidin-4-yl)oxy) phenyl)acrylamide, and formulations thereof
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
CN110407840A (zh) * 2019-08-15 2019-11-05 重庆化工职业学院 一种艾维替尼的制备方法
BR112023002031A2 (pt) 2020-08-14 2023-03-07 Novartis Ag Derivados de espiropiperidinila substituídos por heteroarila e usos farmacêuticos dos mesmos
CN111848631B (zh) * 2020-08-28 2022-04-19 四川大学华西医院 一种靶向EGFR突变的吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途
CN114573591B (zh) * 2022-04-16 2023-04-25 成都施贝康生物医药科技有限公司 一种取代的吡咯并嘧啶化合物及其应用
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
WO2024092047A1 (en) 2022-10-26 2024-05-02 Sorrento Therapeutics, Inc. Administration of pyrrolopyrimidine-based kinase inhibitors for treatment of psoriasis
CN120737091B (zh) * 2025-08-29 2025-11-04 四川大学华西医院 一种以7-脱氮鸟嘌呤为骨架的化合物、药物组合物及用途

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3974277A (en) 1974-09-06 1976-08-10 Diamond Shamrock Corporation 2-[2-(5-Nitro-2-furyl)vinyl]-4-(anilino)quinazolines as growth promotants and feed efficiency enhancing agents
AU1071301A (en) 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
TWI309647B (es) 2001-02-21 2009-05-11 Mitsubishi Tanabe Pharma Corp
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
WO2003026666A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
ATE442587T1 (de) 2002-07-20 2009-09-15 Acea Biosciences Inc Impedanz basierende vorrichtungen und verfahren zur analyse von zellen und partikeln
US7468255B2 (en) 2002-12-20 2008-12-23 Acea Biosciences Method for assaying for natural killer, cytotoxic T-lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology
US7470533B2 (en) 2002-12-20 2008-12-30 Acea Biosciences Impedance based devices and methods for use in assays
US7732127B2 (en) 2002-12-20 2010-06-08 Acea Biosciences, Inc. Dynamic monitoring of cell adhesion and spreading using the RT-CES system
US7560269B2 (en) 2002-12-20 2009-07-14 Acea Biosciences, Inc. Real time electronic cell sensing system and applications for cytotoxicity profiling and compound assays
US7192752B2 (en) 2002-12-20 2007-03-20 Acea Biosciences Real time electronic cell sensing systems and applications for cell-based assays
WO2004021979A2 (en) 2002-09-06 2004-03-18 Smithkline Beecham Corporation PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS
WO2004045624A1 (ja) 2002-11-15 2004-06-03 Mitsubishi Pharma Corporation 医薬製剤組成物
AU2004308299B2 (en) 2003-12-19 2011-11-24 Plexxikon, Inc. Compounds and methods for development of Ret modulators
WO2005065156A2 (en) 2003-12-23 2005-07-21 First Data Corporation Global positioning system
JP2007526339A (ja) 2004-03-02 2007-09-13 ニューロジェン・コーポレーション アリール置換プリン類縁体
WO2006009797A1 (en) 2004-06-17 2006-01-26 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
US7977345B2 (en) 2004-07-02 2011-07-12 Exelixis, Inc. c-MET modulators and method of use
SI1928872T1 (sl) 2005-09-21 2012-06-29 4Sc Ag Novi sulfonilpiroli kot inhibitorji HDAC
CA2625109A1 (en) 2005-10-13 2007-04-19 Glaxo Group Limited Pyrrolopyrimidine derivatives as syk inhibitors
KR100832593B1 (ko) 2005-11-08 2008-05-27 한미약품 주식회사 신호전달 저해제로서의 퀴나졸린 유도체 및 이의 제조방법
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CA2644494A1 (en) 2006-03-03 2007-09-13 Aveo Pharmaceuticals, Inc. Processes for synthesizing 7-alkynyl-4-aminoquinazolines and a related intermediate
WO2007126841A2 (en) 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
WO2008039359A2 (en) 2006-09-25 2008-04-03 Janssen Pharmaceutica N.V. Bicyclic pyrimidine kinase inhibitors
CN103641833A (zh) 2006-12-08 2014-03-19 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
KR20090112732A (ko) 2007-01-26 2009-10-28 아이알엠 엘엘씨 플라스모듐 관련 질환의 치료를 위한 키나제 억제제로서의 퓨린 화합물 및 조성물
JP5539734B2 (ja) 2007-01-31 2014-07-02 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド チオピリミジンベースの化合物およびその使用
WO2008145143A1 (en) 2007-05-30 2008-12-04 Lifecycle Pharma A/S Once daily oral dosage form comprising tacrolimus
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
US7981903B2 (en) 2007-08-08 2011-07-19 Glaxosmithkline Llc 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer
WO2009032703A1 (en) 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
US7982036B2 (en) 2007-10-19 2011-07-19 Avila Therapeutics, Inc. 4,6-disubstitued pyrimidines useful as kinase inhibitors
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
EP2271631B1 (en) 2008-04-22 2018-07-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EA029131B1 (ru) 2008-05-21 2018-02-28 Ариад Фармасьютикалз, Инк. Фосфорсодержащие производные в качестве ингибиторов киназы
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
RU2536584C2 (ru) 2008-06-27 2014-12-27 Авила Терапьютикс, Инк. Гетероарильные соединения и их применение
WO2010045451A1 (en) 2008-10-16 2010-04-22 Glaxosmithkline Llc Pyrrolopyrimidine compounds
CN102307875A (zh) 2009-02-09 2012-01-04 苏伯俭股份有限公司 吡咯并嘧啶基axl激酶抑制剂
EP2440559B1 (en) 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
US20110207736A1 (en) 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
US20130137709A1 (en) 2010-05-05 2013-05-30 Nathanael S. Gray Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
DK2975042T3 (en) 2010-06-23 2019-01-21 Hanmi Science Co Ltd Novel fused pyrimidine derivatives to inhibit tyrosine kinase activity
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
WO2012061299A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
CN102583089B (zh) 2011-01-11 2015-11-25 山东新北洋信息技术股份有限公司 薄片类介质处理装置
BR112013022697A2 (pt) 2011-03-07 2019-09-24 Fond Telethon inibidores de fosforilação de tfeb e usos dos mesmos
WO2012135801A1 (en) 2011-04-01 2012-10-04 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
EA201391626A1 (ru) 2011-05-04 2014-03-31 Ариад Фармасьютикалз, Инк. Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
US9034885B2 (en) * 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US9586965B2 (en) * 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
WO2014025486A1 (en) * 2012-08-06 2014-02-13 Acea Biosciences Inc. Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
WO2013106792A1 (en) 2012-01-13 2013-07-18 Acea Biosciences Inc. Heterocyclic compounds and uses as anticancer agents.
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
RS61664B1 (sr) * 2012-04-24 2021-04-29 Vertex Pharma Inhibitori dna-pk
CN112592334B (zh) 2013-07-11 2023-10-27 艾森医药公司 嘧啶衍生物作为激酶抑制剂
CN104306348B (zh) 2014-09-30 2017-05-31 地奥集团成都药业股份有限公司 一种辛伐他汀片及其制备方法
CN105185339B (zh) 2015-10-08 2017-12-29 京东方科技集团股份有限公司 移位寄存器单元、栅线驱动装置以及驱动方法
EP3359159B1 (en) 2015-10-09 2023-06-07 ACEA Therapeutics, Inc. Pharmaceutical compositions of a pyrrolopyrimidine kinase inhibitor, and methods of making same
CN108290896B (zh) 2015-11-16 2021-09-28 托帕杜制药公司 2-苯基-3,4-二氢吡咯并[2,1-f][1,2,4]三嗪酮衍生物及其用途
EP3606925A1 (en) 2017-04-07 2020-02-12 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same

Also Published As

Publication number Publication date
HK1253537A1 (en) 2019-06-21
CA3001744C (en) 2024-09-27
EP3359159A1 (en) 2018-08-15
EP3359159B1 (en) 2023-06-07
RU2018115334A (ru) 2019-11-11
US20180312510A1 (en) 2018-11-01
WO2017059702A1 (en) 2017-04-13
BR112018006939A2 (en) 2018-10-16
KR20180067584A (ko) 2018-06-20
CA3001744A1 (en) 2017-04-13
AU2016334141A1 (en) 2018-04-26
CN107949388B (zh) 2021-10-26
EP3359159A4 (en) 2019-06-05
US10533011B2 (en) 2020-01-14
RU2018115334A3 (es) 2019-11-29
AU2016334141B2 (en) 2019-12-19
JP2018530610A (ja) 2018-10-18
MX2018004332A (es) 2019-01-10
CN107949388A (zh) 2018-04-20
JP6889494B2 (ja) 2021-06-18
TW201722431A (zh) 2017-07-01

Similar Documents

Publication Publication Date Title
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR110922A1 (es) Compuestos inhibidores del vih
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR094557A1 (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn
AR100886A1 (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
AR088293A1 (es) Inhibidores de proteina cinasa
AR088449A1 (es) Benzilindazoles sustituidos
AR099495A1 (es) Derivados de amida, antagonistas de orexina
AR092742A1 (es) Piridinonas antifibroticas
AR103232A1 (es) ANTAGONISTAS DE TGFbR
AR098872A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
AR091185A1 (es) Derivados de 1,2,4-triazol
AR097866A1 (es) Derivados de 4-azaindol
AR088014A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de la fosfodiesterasa
AR102258A1 (es) Compuestos de quinolina y quinazolina
AR098492A1 (es) Derivados de purina
AR093758A1 (es) Inhibidores de aril lactama quinasa
AR114369A1 (es) Dinucleótidos cíclicos como agentes antineoplásicos
AR097403A1 (es) Derivados de benzamida como antagonistas de lpar1 y/o lpar5 y un proceso para su preparación
AR100940A1 (es) Derivados de 1,2,4-triazoles plaguicidas, y sus intermediarios, composiciones y sus procesos relacionados
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
AR099690A1 (es) Ureas asimétricas p-sustituidas como moduladoras de la actividad de ghrelina

Legal Events

Date Code Title Description
FB Suspension of granting procedure